Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Immunotherapy of cancer

1273 - Phase III randomized controlled trial of adjuvant chemoimmunotherapy in patients with resected primary lung cancer


11 Sep 2017


Immunotherapy of cancer


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Thoracic Malignancies


Hideki Kimura


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


H. Kimura1, Y. Matsui2, T. Nakajima3, T. Iizasa4, A. Ishikawa3

Author affiliations

  • 1 Thoracic Surgery, Saiseikai Narashino Hospital, 2758580 - Narashino city, Chiba/JP
  • 2 Thoracic Surgery, Chiba Cancer Center, 2608717 - Nitona-cho -, Chiba/JP
  • 3 General Thoracic Surgery,, Graduate School of Medicine, Chiba Univercity, 2608670 - Chu-o-ku,Chiba/JP
  • 4 Thoracic Surgery, Chiba Cancer Center, 2608717 - Chu-o-ku,Chiba/JP


Abstract 1273


Adoptive cellar immunotherapy is not widely approved as a treatment option for cancer treatment. The preliminary results from our phase III, randomized controlled trial (RCT) of adjuvant chemoimmunotherapy for lung cancer indicated significant advantages in patients receiving immunotherapy. Here we report the final results and long-term analysis of this RCT.


A hundred and three postsurgical non-small-cell lung cancer patients were randomly designated to receive either chemoimmunotherapy (group A, immunotherapy arm, n = 51) or chemotherapy (group B, control arm, n = 52). The immunotherapy consisted of adoptive transfer of autologous activated killer T cells and dendritic cells obtained from regional lymph nodes of the patients.


The 2- and 5-year overall survival (OS) rates were 96·0% and 69.4% in group A and 64·7% and 45.1% in group B, respectively. The hazard ratio (HR) was 0.451 (0.235∼0.807) by multivariate analysis. The 2- and 5-year recurrence-free survival rates were 70.0% and 57·9% in group A and 43.1% and 31.4% in group B, respectively. P values of Log-rank test between groups were 0.0059. Subgroup analysis for the OS between treatment groups indicated males (HR, 0·474), adenocarcinoma patients (HR, 0·479), stage III cancer patients (HR, 0·399), and those who did not receive preoperative chemotherapy (HR, 0·483) had lower HRs than those in the other groups. Immunological analysis of cell surface markers in regional lymph nodes of subjects receiving immunotherapy indicated that the CD8+/CD4+ T-cell ratio was elevated in survivors.


Non-small-cell lung cancer patients benefited from adoptive cellular immunotherapy as an adjuvant to surgery. Immunological analysis of cell surface markers indicated cytotoxic T cells were essential for a favorable chemoimmunotherapy outcome.

Clinical trial identification

The University Hospital Medical Information Network in Japan (UMIN: 000007525).

Legal entity responsible for the study

Chiba Cancer Center, Japan




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.